TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05766436
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: will receive placebo nebulizer and 0.4mg/kg of ODF melatonin (metacyst ™ nerhadou) orally allowing the film to dissolve in the patients Oro mucosal lining
Study: NCT05766436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo ODF and 0.9% normal saline nebulizer
Study: NCT05230381
Drug: Continous infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by 5mg/kg/h tranexamic acid infusion.
Study: NCT05230381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 0.9% saline is administered with the same volume at the same speed as the other group.
Study: NCT05380713
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be applied in the neoadjuvant setting
Study: NCT05365321
Drug: WP1122
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses from 8 mg/kg will be increased in doubling increments up to 64 mg/kg in the dose escalation Phase 1 portion of the study, administered orally (PO) for 10 days q12h ±1h. The dose in Phase 2 will utilize the Maximum Tolerated Dose (MTD) established in Phase 1 and also administered PO q12h ± 1h for 10 days.
Study: NCT05190744
Drug: PB
Normalized name: PBG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg twice daily (BID) followed by 1000mg BID. The dose of PB inducing the maximal increase in urine osmolality will be continued for up to three months providing that no side effects are observed including clinical and laboratory surveillance.
Study: NCT05720767
Drug: HMPL-523
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-523 is a selective small-molecule SYK inhibitor.
Study: NCT06107036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching BI 101550
Study: NCT05035472
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT04629703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily) for 14 days and Standard of Care
Study: NCT05217342
Drug: Diuretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diuretic therapy according to the current guidelines
Study: NCT00669786
Drug: Human Menopausal Gonadotropin (HMG) & - Recombinant Follicle Stimulating Hormone (r-FSH)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06481709
Drug: RLF-OD032
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/mL oral suspension
Study: NCT04766684
Drug: L.M.X.4 cream with J-Tip saline injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: L.M.X.4 cream with J-Tip saline injection
Study: NCT05330221
Drug: PHARM-PAL2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All intervention arm participants will be referred to our study pharmacist who will prescribe a antihypertensive medication as per standard of care medical treatment algorithm to achieve BP control.~Per AHA recommended guidelines, participants with an indication of diabetes mellitus (DM) and/or CKD will be started on SGLT2 inhibitor within the first month of starting the study intervention.
Study: NCT00339118
Drug: doxorubicin, cytoxan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04621110
Drug: intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl will be administered by intranasal route in 1,5ug/kg each dose, repeating at most 3 times to see if it can give enough pain relief for painful procedure. To assess pain control the study will use Face, Legs, Activity, Cry, Consolability scale ( FLACC)
Study: NCT06122714
Drug: Placebo Part A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Participants will be administered a single oral dose of matching placebo on Day 1.
Study: NCT06122714
Drug: Placebo Part B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: Participants will be administered a single dose of matching placebo on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
Study: NCT05919693
Drug: EYE103
Approvals — FDA: no, EMA: no, PMDA: no
Description: EYE103 is a humanized antibody formulated for IVT administration
Study: NCT05092191
Drug: Cannabis oil vs placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligibility, Screening and Baseline (T0):~Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .~Follow-up visits:~Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.~At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.~Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being.
Study: NCT05823285
Drug: QLS31903
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01μg/kg-2.16 μg/kg QLS31903 for injection
Study: NCT06723366
Drug: Angong Niuhuang Pill (ANP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angong Niuhuang Pill (ANP) (3 g/pill, 1 pill/day for 5 days)
Study: NCT05064332
Drug: Ethinyl estradiol (EE) and levonogestrel (LN)
Normalized name: estradiol / ethinyl estradiol / levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
Study: NCT06731894
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04296695
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: randomized, multicentered, open-lable RCT, one arm with B/F/TAF and one arm with TDF/3TC/EFV
Study: NCT04296695
Drug: TDF/3TC/EFV
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/3TC/EFV
Study: NCT04584034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be delivered using a Babyhaler spacer device. The placebo will contain only the propellant HFA 134a.
Study: NCT05129319
Drug: prabotulinumtoxinA
Normalized name: PrabotulinumtoxinA
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of glabellar rhytids
Study: NCT06511336
Drug: Alkaline water (FLO water- Bottled drinking water- the Egyption Saudi Company for natural water- made in Egypt
Approvals — FDA: no, EMA: no, PMDA: no
Description: children will use Alkaline water as mouthwash daily for 3 weeks. each time they will use 10 ml of their mouthwash for 30 seconds
Study: NCT03468556
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take 2 tablets once a day orally for 12 weeks
Study: NCT06055361
Drug: BxC-I17e
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form : solution for injection
Study: NCT06514144
Drug: BGF
Normalized name: ALCOHOL 620 mg in 1 g TOPICAL AEROSOL, FOAM [GBGF]
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide/glycopyrrolate/formoterol fumarate
Study: NCT04763057
Drug: NeoPUTTY MTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeoPUTTY, a premixed bioactive bioceramic MTA that triggers hydroxyapatite and supports healing
Study: NCT04763057
Drug: calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide the gold standard for IPT
Study: NCT06055361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form : solution for injection
Study: NCT05303779
Drug: Medication and eye glasses
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: medication and eye glasses used post strabismus surgery
Study: NCT05695781
Drug: BRM421 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: A topical drop of BRM421 ophthalmic solution.
Study: NCT05695781
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: A topical drop of vehicle (minus active) ophthalmic solution.
Study: NCT06457828
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: infiltration injection of 0.7 ml of dexamethasone lateral to the involved tooth after anesthesia administration.
Study: NCT05382312
Drug: GSK3036656
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3036656 will be administered.
Study: NCT05264025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT06732154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride injection
Study: NCT06732895
Drug: Navepegritide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly subcutaneous injection of 100 µg/kg navepegritide for 52 weeks
Study: NCT06732895
Drug: Placebo for navepegritide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly subcutaneous injection of 100 µg/kg placebo for navepegritide
Study: NCT06162650
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, infusinal 5-fluorouracil 2400 mg/m2 every 2 weeks, for 9 cycles
Study: NCT04406948
Drug: MGCND00EP1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take cannabis oil during the study
Study: NCT04406948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will take carrier oil during the study
Study: NCT05884281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for treatment period
Study: NCT05519579
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration
Study: NCT06579703
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized to a single dose of:~Arm A: 15 mg/mL (per mL) Arm B: 30 mg/mL (per mL)
Study: NCT05244538
Drug: Propofol-remifentanil sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target controlled infusion (TCI) of remifentanil will be started at an effect concentration (Ce) of 1.5 ng/mL and TCI propofol at Ce 1.5 ug/mL.~The concentration of remifentanil will be adjusted in 0.5 ng/ml increments based on hand sign from the patient with a maximum effect concentration of remifentanil at 2.5 ng/ml.
Study: NCT05934812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo liquid nasal spray administered twice-daily
Study: NCT06571448
Drug: SR750 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR750 high dose BID orally for 6 weeks
Study: NCT06571448
Drug: SR750 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR750 low dose BID orally for 6 weeks
Study: NCT06571448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01512901
Drug: Betamethasone Microsphere (DE-102） High Dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05488626
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy per NCCN or other national guidelines.
Study: NCT05488626
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant immunotherapy per national or institutional guidelines.
Study: NCT04732455
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.
Study: NCT04735549
Drug: Topical hormone estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Daily dose will be 0.5 gram daily for 2 weeks, later 0.5 gram twice a week for 12 months.
Study: NCT04688242
Drug: administration of probiotics (Clostridium butyricum TO-A; Bacillus mesentericus TO-A; Streptococcus faecalisT-110) per anus
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
Study: NCT04766151
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal placebo patches applied to skin 30 minutes before cardiac catheterization
Study: NCT05089617
Drug: YG1699
Approvals — FDA: no, EMA: no, PMDA: no
Description: YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~Drug: Placebo~Placebo is the same appearance as YG1699.
Study: NCT06199557
Drug: Hydroxyurea, Hydroxycarbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU/hydroxycarbamide) is a hydroxylated analogue of urea which prevents DNA synthesis by inhibiting the activity of ribonucleotide reductase (RNR). HU has been used to treat a variety of diseases. As an antineoplastic drug, HU has some advantages. It may be used by ambulatory patients and has relatively few side effects, which are relieved almost immediately after withdrawal of the drug. The drug is readily absorbed from the gastrointestinal tract following oral administration. At present, HU has an important role as standard of care for treating hyperleukocytosis in chronic and acute myeloid leukemia.
Study: NCT05085587
Drug: Test
Normalized name: Testro
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT05085587
Drug: Reference
Normalized name: Loreal Preference Dark Auburn 4R
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT00112879
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04151225
Drug: GSK2330811
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.
Study: NCT04151225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be available as SC injection of 0.9 percent saline solution. It will be available as single-use pre-filled syringe.
Study: NCT05056779
Drug: CD14152 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive loading dose of 60 mg (2×30 mg) SC injection of placebo at baseline. Thereafter 30 mg placebo will be administered via single SC injection Q4W up to week 12.
Study: NCT05496374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching capsules will be administered orally.
Study: NCT05496374
Drug: SPR720 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPR720 500 mg (250 mg × 2 capsules) will be administered orally.
Study: NCT05004987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of placebo will mimic that of ESC.
Study: NCT06717685
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine is a medication belonging to class V antidysrhythmics, used to treat a type of irregular heart rhythm disorder known as paroxysmal supraventricular tachycardia (PSVT)
Study: NCT06733402
Drug: AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG
Approvals — FDA: no, EMA: no, PMDA: no
Description: A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
Study: NCT06733402
Drug: AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
Study: NCT06733402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
Study: NCT06732518
Drug: Fluoride free toothpaste in a PCC/RNCC base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride free toothpaste in a PCC/RNCC base
Study: NCT01629420
Drug: KLH-2109
Normalized name: LINZAGOLIX CHOLINE 1 kg in 1 kg POWDER [KLH-2109 Choline]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04909242
Drug: DZD9008
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive DZD9008 at different dose levels. There are 5 planned dose cohorts, starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008 or matching placebo, namely 100 mg, 200 mg, 300 mg and 400 mg.
Study: NCT04909242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive matching placebo for DZD9008 at different dose levels. There are 5 planned dose cohorts of matching placebo for DZD9008, starting from 50 mg once daily.
Study: NCT04909242
Drug: DZD9008
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part C, healthy adult participants will be enrolled to receive a single dose of DZD9008 as suspension in period 1 and as tablet in period 2.
Study: NCT04909242
Drug: DZD9008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy adult participants will be randomized to receive DZD9008 single dose at a defined dose under a cross-over condition with or without food (low-fat in Part B; high-fat in Part D).
Study: NCT04701151
Drug: Bacillus Calmette Guerin
Normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.
Study: NCT05097846
Drug: Group1 Vonoprazan Fumarate + amoxicillin + doxycycline
Normalized name: AMOXICILLIN/VONOPRAZAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan Fumarate + amoxicillin + doxycycline
Study: NCT05097846
Drug: Group2 Vonoprazan Fumarate + furazolidone + doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan Fumarate + furazolidone + doxycycline
Study: NCT05097846
Drug: Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
Study: NCT05097846
Drug: Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
Study: NCT06138990
Drug: Clinical standard-of-care (physician's choice)
Normalized name: Doctor's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).
Study: NCT05431569
Drug: 6MW3211
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6MW3211 injection ,30mg/kg,iv drip，Q2W
Study: NCT05691257
Drug: Recombinant human eythropoietin and/or Iron agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drugs to treat anemia include: Recombinant human eythropoietin (RH-EPO), iron agents (ferrous succinate, polysaccharide iron complex, iron sucrose, etc.)
Study: NCT04833764
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration of 20 mg rosuvastatin for at least 3 months
Study: NCT06412653
Drug: Zinc Acetate Dihydrate
Normalized name: Zinc Acetate Dihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this single arm trial, all participants will be receive the trial drug zinc acetate dihydrate orally. The Investigational medicinal product (IMP) will be given one hour after meal in a dosage which is recommended in Wilson Disease and has been given in this condition without observing severe adverse effects. If oral administration is not possible due to the disability level of the patient, the IMP can be mortared and suspended and can then be given as suspension orally or via the Percutaneous endoscopic gastrostomy. The total treatment duration in each patient is 6 months with stable dosage over the duration of the trial. If the therapy shows effects, the parents and participants may continue medication after the end of the trial. If not, they will stop the medication after the last visit at the trial site.
Study: NCT06052241
Drug: shampoos and scalp serums
Normalized name: Selsun Blue Sensitive Scalp Shampoo Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: shampoos and scalp serums personalized according to their SPI-AI-defined scalp types
Study: NCT06198465
Drug: adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: adebrelimab: 1200mg，D1，q3w; Paclitaxel: 50mg/m2 D1/8/15； Lobaplatin: 50mg，iv 2h，d1; Fluorouracil: 400mg/m2，bolus iv，600mg/m2，iv 22h，d1-3；
Study: NCT05547243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution
Study: NCT04844580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aviptadil Placebo will be used for this arm.
Study: NCT04482413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control group receive 20 mL of Saline and auto serum every 4 weeks from Week 0 to Week 36.
Study: NCT05855330
Drug: Arginine Hydrochloride
Normalized name: Arginine Hydrochloride
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine will be infused based on the manufacturer's instructions (R-Gene 10, Pfizer), over 30 minutes. However, rates may be slowed to over 60 minutes for patients experiencing symptoms of flushing, nausea, vomiting, or headache at the research team's discretion. Pediatric doses will be drawn up by the pharmacy.
Study: NCT06324266
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Cyclophosphamide monotherapy for 2 years.